Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is to give more intensive treatment to patients whose PET/CT shows that they have a greater chance of still having active lymphoma (PET/CT scan is positive after 3 cycles of therapy), and to give less intensive treatment to patients whose PET/CT scan shows that they have a smaller chance of still having active lymphoma (PET/CT scan is negative after 3 cycles of therapy). Participants in this study have limited (or early stage) Diffuse Large B Cell non-Hodgkin Lymphoma (DLBCL). Limited (or early) Stage Diffuse Large B-cell non-Hodgkin Lymphoma is curable in many people, but some still can relapse (the cancer comes back), and some develop side-effects during or after treatment. A radiologic test called PET/CT scan is used in this study to determine treatment after three (3) cycles of a standard lymphoma chemotherapy called R-CHOP (the drugs are Rituximab, Cyclophosphamide, vincristine, doxorubicin, and prednisone). The agents used in this study are FDA approved for lymphoma treatment.
Back to Clinical Trials list